Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity

Show full item record



Permalink

http://hdl.handle.net/10138/310485

Citation

Santos , J M , Heiniö , C , Cervera-Carrascon , V , Quixabeira , D C A , Siurala , M , Havunen , R , Butzow , R , Zafar , S , de Gruijl , T , Lassus , H , Kanerva , A & Hemminki , A 2020 , ' Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity ' , Journal for Immunotherapy of Cancer , vol. 8 , no. 1 , 000188 . https://doi.org/10.1136/jitc-2019-000188

Title: Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity
Author: Santos, João Manuel; Heiniö, Camilla; Cervera-Carrascon, Victor; Quixabeira, Dafne C A; Siurala, Mikko; Havunen, Riikka; Butzow, Ralf; Zafar, Sadia; de Gruijl, Tanja; Lassus, Heini; Kanerva, Anna; Hemminki, Akseli
Contributor organization: TRIMM - Translational Immunology Research Program
Research Programs Unit
Faculty of Medicine
University of Helsinki
Medicum
University Management
HUS Comprehensive Cancer Center
Department of Oncology
HUS Gynecology and Obstetrics
Department of Obstetrics and Gynecology
Akseli Eetu Hemminki / Principal Investigator
Date: 2020-01
Language: eng
Number of pages: 15
Belongs to series: Journal for Immunotherapy of Cancer
ISSN: 2051-1426
DOI: https://doi.org/10.1136/jitc-2019-000188
URI: http://hdl.handle.net/10138/310485
Abstract: BACKGROUND: Ovarian cancers often contain significant numbers of tumor-infiltrating lymphocytes (TILs) that can be readily harnessed for adoptive T-cell therapy (ACT). However, the immunosuppressive ovarian tumor microenvironment and lack of tumor reactivity in TILs can limit the effectiveness of the therapy. We hypothesized that by using an oncolytic adenovirus (Ad5/3-E2F-D24-hTNFa-IRES-hIL2; TILT-123) to deliver tumor necrosis factor alpha (TNFa) and interleukin-2 (IL-2), we could counteract immunosuppression, and enhance antitumor TIL responses in ovarian cancer (OVCA). METHODS: We established ex vivo tumor cultures freshly derived from patients with advanced OVCA and evaluated the effects of Ad5/3-E2F-D24-hTNFa-IRES-hIL2 or Ad5/3-E2F-D24 (the control virus without TNFa and IL-2) on TILs, cytokine response and tumor viability. Tumor reactivity was assessed by determining interferon gamma (IFNg) response of clinically relevant TILs towards autologous T-cell-depleted ex vivo tumor cultures pretreated with or without the aforementioned oncolytic adenoviruses. RESULTS: Treatment of ex vivo tumor cultures with Ad5/3-E2F-D24-hTNFa-IRES-hIL2 caused a substantial rise in proinflammatory signals: increased secretion of IFNg, CXCL10, TNFa and IL-2, and concomitant activation of CD4+ and CD8+ TILs. Potent tumor reactivity was seen, as clinically relevant TIL secreted high levels of IFNg in response to autologous T-cell-depleted ovarian ex vivo tumor cultures treated with Ad5/3-E2F-D24-hTNFa-IRES-hIL2. This phenomenon was independent of PD-L1 expression in tumor cells, a factor that determined the variability of IFNg responses seen in different patient samples. CONCLUSIONS: Overall, oncolytic adenovirus Ad5/3-E2F-D24-hTNFa-IRES-hIL2 was able to rewire the ovarian tumor microenvironment to accommodate heightened antitumor TIL reactivity. Such effects may improve the clinical effectiveness of ACT with TILs in patients with advanced OVCA.
Subject: 3111 Biomedicine
TIL therapy
adenovirus
immunotherapy
oncolytic virus
tumor microenvironment
tumor-infiltrating lymphocytes
CANCER-CELLS
IMMUNE-RESPONSE
PD-L1 EXPRESSION
NECROSIS-FACTOR-ALPHA
ADOPTIVE CELL THERAPY
METASTATIC MELANOMA
FAVORABLE PROGNOSIS
IN-VIVO
REGULATORY T-CELLS
COMPLETE RESPONSES
Peer reviewed: Yes
Rights: cc_by_nc
Usage restriction: openAccess
Self-archived version: publishedVersion


Files in this item

Total number of downloads: Loading...

Files Size Format View
e000188.full.pdf 2.219Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record